Licensing & Pipeline

We acquire or license clinical-stage assets and leverage our tech-driven platform to develop them, generating more value per program by reaching the next value inflection point in the development lifecycle faster and more efficiently. By developing our portfolio assets faster than industry norms, we can take more shots on goal, increasing the likelihood of success for us and our partners.

How We Operate

At Formation Bio we create more value per drug program by leveraging our proprietary platform to develop promising drug candidates. Our core competencies include:

  • Faster drug development through proprietary tech-driven platform
  • Best in class team across drug selection, drug development, and tech
  • Flexible structures and financing pathways

Our Pipeline

ASN008

Sodium Channel Blocker

Modality: Small Molecule

Indication

Stage

Itch associated with Atopic Dermatitis

Phase 2

Gusacitinib

SYK/JAK Inhibitor

Modality: Small Molecule

Indication

Stage

Chronic Hand Eczema

Phase 3

Sprifermin

Recombinant human fibroblast growth factor 18 (FGF18)

Modality: Biologic

Indication

Stage

Knee Osteoarthritis

Phase 2

Interested in joining our team? Visit our Careers page.

© Formation Bio 2024
Site Credit